849067-96-5

Basic information

• Product Name: 1H-PYRROLO[2,3-B]PYRIDINE-5-CARBOXYLIC ACID METHYL ESTER
• Synonyms: 1H-PYRROLO[2,3-B]PYRIDINE-5-CARBOXYLIC ACID METHYL ESTER;1H-PYRAZOLO[2,3-B]PYRIDINE-5-CARBOXYLIC METHYL ESTER;Methyl 7-azaindole-5-carboxylate;Methyl 7-azaindole-5-carb...;Methyl 1H-pyrrolo[2,3-b]pyridine-5-carboxylate;1H-Pyrrolo[2,3-b]pyridin-5-carboxylic acid methyl ester;7-Azaindole-5-carboxylic acid Methyl ester ;H-Pyrrolo[2,3-b]pyridine-5-carboxylicacidMethylester
• CAS NO: 849067-96-5
• Molecular Formula: C₉H₈N₂O₂
• Molecular Weight: 176.17
• Product Categories: Heterocycle-Pyridine series
• Mol File: 849067-96-5.mol

Chemical Properties

• Appearance: /
• Density: 1.32
• Refractive Index: 1.648
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 12.97±0.40(Predicted)
• CAS DataBase Reference: 1H-PYRROLO[2,3-B]PYRIDINE-5-CARBOXYLIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-PYRROLO[2,3-B]PYRIDINE-5-CARBOXYLIC ACID METHYL ESTER(849067-96-5)
• EPA Substance Registry System: 1H-PYRROLO[2,3-B]PYRIDINE-5-CARBOXYLIC ACID METHYL ESTER(849067-96-5)

Safety Data

• Hazard Codes: Xi
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 849067-96-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1H-PYRROLO[2,3-B]PYRIDINE-5-CARBOXYLIC ACID METHYL ESTER is used as a building block for the synthesis of various pharmaceuticals due to its heterocyclic structure and potential therapeutic applications.
Used in Agrochemical Industry:
1H-PYRROLO[2,3-B]PYRIDINE-5-CARBOXYLIC ACID METHYL ESTER is used as a building block in the synthesis of agrochemicals, contributing to the development of new compounds for agricultural applications.
Used in Chemical Synthesis:
1H-PYRROLO[2,3-B]PYRIDINE-5-CARBOXYLIC ACID METHYL ESTER is used as a versatile compound in chemical synthesis, taking advantage of its solubility in organic solvents and its ability to be incorporated into various molecular structures.

InChI:InChI=1/C9H8N2O2/c1-13-9(12)7-4-6-2-3-10-8(6)11-5-7/h2-5H,1H3,(H,10,11)

Upstream product

• 183208-35-7 5-bromo-1H-pyrrolo[2,3-b]pyridine 
• 754214-42-1 1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid 
• 67-56-1 methanol 
• 517918-95-5 1H-pyrrolo[2,3-b]pyridine-5-carbonitrile 
• 186581-53-3 diazomethane 
• 13939-06-5 molybdenum hexacarbonyl 
• 36052-24-1 methyl 6-aminonicotinoate 
• 211308-80-4 2-amino-3-iodo-5-nicotinic methyl ester 
• 1312021-02-5 6-acetylamino-5-trimethylsilanylethynyl nicotinic acid methyl ester 
• 1312017-75-6 methyl 6-amino-5-((trimethylsilyl)ethynyl)nicotinate 
• 201230-82-2 carbon monoxide 
• 849067-95-4 1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid methyl ester 

Downstream Products

• 849067-97-6 (1H-pyrrolo[2,3-b]pyridin-5-yl)methanol 
• 1083181-12-7 1-benzenesulfonyl-1H-pyrrolo[2,3-b]pyridin-5-carboxylic acid methyl ester 
• 1086422-83-4 N-(2-methyl-5-((4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxamide 
• 1581701-36-1 N-(3-((4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxamide 
• 1581701-37-2 N-(2-ethyl-5-((4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxamide 
• 1581701-38-3 N-(2-isopropyl-5-((4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxamide 
• 1294501-86-2 C₂₁H₁₆F₂N₄O₂ 
• 849067-95-4 1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid methyl ester 
• 1621399-44-7 C₂₀H₂₂FN₅O₂ 
• 1621399-63-0 C₂₅H₃₀FN₅O₄ 
• 1403746-51-9 1-tert-butyl 5-methyl 3-iodo-1H-pyrrolo[2,3-b]pyridine-1,5-dicarboxylate 
• 944937-30-8 methyl 3-iodo-1H-pyrrolo[2,3-b]pyridine-5-carboxylate 
• 1201324-18-6 C₁₆H₁₃ClN₂O₂ 
• 1201324-17-5 5-fluoro-2-[1-(4-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]oxazolo[5,4-b]pyridine 

Relevant articles and documents

SUBSTITUTED 3-PIPERIDINYL-PYRROLO[2,3-B]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS

The invention provides substituted 3-piperidinyl-pyrrolo[2,3-b]pyridines and related compounds, pharmaceutical compositions, their use for inhibiting ERK5 activity, and their use in the treatment of medical disorders, such as cancer.

Selective inhibition of Helicobacter pylori methionine aminopeptidase by azaindole hydroxamic acid derivatives: Design, synthesis, in vitro biochemical and structural studies

Methionine aminopeptidases (MetAPs) are an important class of enzymes that work co-translationally for the removal of initiator methionine. Chemical inhibition or gene knockdown is lethal to the microbes suggesting that they can be used as antibiotic targ

PGDH INHIBITORS AND METHODS OF MAKING AND USING

Disclosed herein are compounds that can inhibit 15-hydroxyprostaglandin dehydrogenase. Such compounds may be administered to subjects that may benefit from modulation of prostaglandin levels.

cGAS ANTAGONIST COMPOUNDS

Disclosed are novel compounds of Formula (I) that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.

GPR40 RECEPTOR AGONIST, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT

The present invention relates to a novel compound having GPR40 receptor agonist activity that promotes insulin secretion and inhibits blood sugar rise after glucose loading, and is thereby useful for the treatment of diabetes and complications thereof, the preparation method thereof and pharmaceutical composition containing them as an active ingredient.

Identification and optimization of new dual inhibitors of B-Raf and epidermal growth factor receptor kinases for overcoming resistance against vemurafenib

Epidermal growth factor receptor (EGFR) amplification has been demonstrated to be critical for the inherent and/or acquired resistance against current B-RafV600E inhibitor therapy for melanoma and colorectal cancer patients. We describe the discovery and structure-activity relationship study of a series of 1H-pyrazolo[3,4-b]pyridine-5-carboxamide analogues as novel dual inhibitors of EGFR and B-RafV600E mutant. One of the most promising compounds, 6a, potently inhibited both of the kinases with IC50 values of 8.0 and 51 nM, respectively. The compound also strongly suppressed the proliferation of a panel of intrinsic and acquired resistant melanoma and/or colorectal cancer cells harboring overexpressed EGFR with submicromolar IC 50 values. Further mechanism investigation revealed that 6a could sustainably inhibit the activation of the MAPK path way in the resistant SK-MEL-28 PR30 melanoma cancer cells and WiDr colorectal cancer cells with EGFR amplification. Our results support the hypothesis that the EGFR/B-Raf V600E dual inhibition might be a tractable strategy to overcome the intrinsic and acquired resistance of melanoma and/or colorectal cancers against the current B-RafV600E inhibitor therapy.

COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE

The present invention provides a compound, that is a 1-({halo-2-[(2-hydrocarbyl or substituted hydrocarbyl)oxy]phenyl}methyl)-(fused bicyclic nitrogen heteroaryl) carboxylic acid or an ester or sulfonamide thereof. The compound may be represented by the f

AZAINDOLE GLUCOKINASE ACTIVATORS

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.

PYRAZOLE COMPOUNDS

The present invention is directed to compounds of Formula (I) and to pharmaceutically acceptable salts thereof, their synthesis, and their use as Raf inhibitors.

PYRROLO[2,3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS

Compounds of formula III which are active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.